For research use only. Not for therapeutic Use.
ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system[1][2][3].
ANG1005 shows significantly improved delivery to brain and brain metastases of breast cancer compared to free paclitaxel (HY-B0015)[1].
| Catalog Number | I041862 |
| CAS Number | 1075214-55-9 |
| Molecular Formula | C257H308N32O79 |
| Purity | ≥95% |
| Reference | [1]. Thomas FC, et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res. 2009 Nov;26(11):2486-94. [2]. Li F, et al. Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB). Genes Dis. 2017 Feb 10;4(1):1-3. [3]. Kumthekar P, et al. ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clin Cancer Res. 2020 Jun 15;26(12):2789-2799. |
